Influenza vaccination: Options and issues

Hong Kong Medical Journal

Volumn 11, Issue 5, 2005, Pages 381-390

  Wong, S S Y ^a   Yuen, K Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Influenza; Influenza vaccines; Vaccines, attenuated; Vaccines, inactivated

Indexed keywords

ADJUVANT; AGRIPPAL S1; AMINOGLYCOSIDE; CETRIMIDE; DEOXYCHOLATE SODIUM; EGG PROTEIN; ENDOTOXIN; EXCIPIENT; FLUVAX; FLUVIRAL; FORMALDEHYDE; GENTAMICIN; INACTIVATED VACCINE; INFLUENZA VACCINE; KANAMYCIN; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NASALFLU; NEOMYCIN; OCTOXINOL; PARACETAMOL; PHOSPHATIDYLCHOLINE; POLYMYXIN; POLYSORBATE 80; PROPIOLACTONE; SUCROSE; TAURODEOXYCHOLIC ACID; THIOMERSAL; TRITON X 100; UNCLASSIFIED DRUG; VIROSOME;

ARTHRALGIA; CHILL; CLINICAL TRIAL; COUGHING; DRUG ADMINISTRATION ROUTE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG PURIFICATION; DYSPNEA; EDEMA; ERYTHEMA; EYE DISEASE; EYE PAIN; FACIAL NERVE PARALYSIS; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; INFLAMMATION; INFLUENZA; INFLUENZA VACCINATION; LYMPHADENOPATHY; META ANALYSIS; MUSCULOSKELETAL DISEASE; MYALGIA; NONHUMAN; NOSE CONGESTION; OCULAR PRURITUS; PAIN; RESPIRATORY TRACT DISEASE; REVIEW; RHINORRHEA; SECRETORY OTITIS MEDIA; SIDE EFFECT; SKIN INDURATION; SYSTEMATIC REVIEW; THORAX PAIN; VIRUS STRAIN; VISUAL IMPAIRMENT; WHEEZING;

HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 27144433873     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Brown EG. Influenza virus genetics. Biomed Pharmacother 2000;54:196-209.
2. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2005-2006 influenza season. Wkly Epidemiol Rec 2005;80:71-5.
3. HKSAR Department of Health website: http://www.psdh.gov. hk/pharmsearch/index.jsp. Accessed 26 Apr 2005.
4. Master Index of Medical Specialties (MIMS). Hong Kong: MediMedia; 2005.
5. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998;16:960-8.
6. Bruhl P, Kerschbaum A, Kistner O, Barrett N, Dorner F, Gerencer M. Humoral and cell-mediated immunity to vero cell-derived influenza vaccine. Vaccine 2000;19:1149-58.
7. Maassab HF, DeBorde DC. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 1985;3:355-69.
8. Beyer WE, Palache AM, de Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002;20:1340-53.
9. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-80.
10. Ruf BR, Colberg K, Frick M, Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004;32:191-8.
11. Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 2002;20 (Suppl 5):B17-23.
12. Chaloupka I, Schuler A, Marschall M, Meier-Ewert H. Comparative analysis of six European influenza vaccines. Eur J Clin Microbiol Infect Dis 1996;15:121-7.
13. European Pharmacopoeia Commission. European Pharmacopoeia. 4th ed. Strausbourg: Council of Europe; 2002.
14. British Pharmacopoeia Commission. British Pharmacopoeia. London: The Stationery Office; 2004.
15. Herzog C, Metcalfe IC, Schaad UB. Virosome influenza vaccine in children. Vaccine 2002;20(Suppl 5):B24-8.
16. Sendi P, Locher R, Bucheli B, Battegay M. Intranasal influenza vaccine in a working population. Clin Infect Dis 2004;38:974-80.
17. Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines. Clin Drug Invest 1998;15:1-12.
18. Boulianne N, de Serres G, Duval B, Shadmani R, Rochette L. Clinical manifestations and incidence of oculo-respiratory syndrome following influenza vaccination-Quebec, 2000. Can Commun Dis Rep 2001;27:85-90.
19. De Serres G, Grenier JL, Toth E, et al. The clinical spectrum of the oculo-respiratory syndrome after influenza vaccination. Vaccine 2003;21:2354-61.
20. Skowronski DM, De Serres G, Scheifele D, et al. Randomized, double-blind, placebo-controlled trial to assess the rate of recurrence of oculorespiratory syndrome following influenza vaccination among persons previously affected. Clin Infect Dis 2003;37:1059-66.
21. De Serres G, Skowronski DM, Guay M, et al. Recurrence risk of oculorespiratory syndrome after influenza vaccination: randomized controlled trial of previously affected persons. Arch Intern Med 2004;164:2266-72.
22. Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 1984;119:841-79.
23. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.
24. Geier MR, Geier DA, Zahalsky AC. Influenza vaccination and Guillain Barré syndrome. Clin Immunol 2003;107:116-21.
25. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barré syndrome following influenza vaccination. JAMA 2004;292:2478-81.
26. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004;23:138-44.
27. Redding G, Walker RE, Hessel C, et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2002;21:44-8.
28. Negri E, Colombo C, Giordano L, Groth N, Apolone G, La Vecchia C. Influenza vaccine in healthy children: a meta-analysis. Vaccine 2005;23:2851-61.
29. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000;18:957-1030.
30. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-27.
31. Vu T, Parish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002;20:1831-6.
32. Künzel W, Glathe H, Engelmann H, van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996;14:1108-10.
33. Delafuente JC, Davis JA, Meuleman JR, Jones RA. Influenza vaccination and warfarin anticoagulation: a comparison of subcutaneous and intramuscular routes of administration in elderly men. Pharmacotherapy 1998;18:631-6.
34. Raj G, Kumar R, McKinney WP. Safety of intramuscular influenza immunization among patients receiving long-term warfarin anticoagulation therapy. Arch Intern Med 1995;155:1529-31.
35. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004;351:2295-301.
36. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351:2286-94.
37. Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis 2002;2:327-43.
38. Govaert TM, Sprenger MJ, Dinant GJ, Aretz K, Masurel N, Knottnerus JA. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 1994;12:1185-9.
39. Beyer WE, Palache AM, Baljet M, Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989;7:385-94.
40. Gross PA, Weksler ME, Quinnan GV Jr, Douglas RG Jr, Gaerlan PF, Denning CR. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol 1987;25:1763-5.
41. Buxton JA, Skowronski DM, Ng H, et al. Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks. J Infect Dis 2001;184:188-91.
42. Roos-Van Eijndhoven DG, Cools HJ, Westendorp RG, Ten Cate-Hoek AJ, Knook DL, Remarque EJ. Randomized controlled trial of seroresponses to double dose and booster influenza vaccination in frail elderly subjects. J Med Virol 2001;63:293-8.
43. McElhaney JE, Hooton JW, Hooton N, Bleackley RC. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 2005;23:3294-300.
44. Vogtländer NP, Brown A, Valentijn RM, Rimmelzwaan GF, Osterhaus AD. Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients. Vaccine 2004;22:2199-201.
45. Brydak LB, Machala M. Humoral immune response to influenza vaccination in patients from high risk groups. Drugs 2000;60:35-53.
46. Kroon FP, van Dissel JT, de Jong JC, Zwindermann K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000;18:3040-9.
47. Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 2003;16:357-64.
48. Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am J Med 1997;102(3A):55-60,75-6.
49. King JC Jr, Fast PE, Zangwill KM, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001;20:1124-31.
50. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB; Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004;53:1-40.
51. Bigham M, Copes R. Thiomersal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease. Drug Saf 2005;28:89-101.
52. Gemmill I. National Advisory Committee on Immunization (NACI). Statement on thimerosal. Can Commun Dis Rep 2003;29:1-10.
53. James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998;133:624-8.
54. Zeiger RS. Current issues with influenza vaccination in egg allergy. J Allergy Clin Immunol 2002;110:834-40.
55. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995;332:1262-6.
56. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000;355:93-7.
57. Demicheli V, Rivetti D, Decks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004;3:CD001269.
58. Scientific Committee on Vaccine Preventable Diseases Statements on Influenza Vaccination for the 2004/05 Season. HKSAR Centre for Health Protection website: http://www.chp. gov.hk/files/pdf/sas-Flu-recommendations-en-20040927. pdf. Accessed 26 Apr 2005.
59. Avian influenza: assessing the pandemic threat. 2005. World Health Organization website: http://www.who.int/csr/disease/ influenza/WHO_CDS_2005_29/ en/. Accessed 26 Apr 2005.
60. Centers for Disease Control and Prevention (CDC). Interventions to increase influenza vaccination of health-care workers-California and Minnesota. MMWR Morb Mortal Wkly Rep 2005;54:196-9.
61. Salgado CD, Giannetta ET, Hayden FG, Farr BM. Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians. Infect Control Hosp Epidemiol 2004;25:923-8.
62. Sartor C, Tissot-Dupont H, Zandotti C, Martin F, Roques P, Drancourt M. Use of a mobile cart influenza program for vaccination of hospital employees. Infect Control Hosp Epidemiol 2004;25:918-22.
63. Enserink M. Influenza. Crisis underscores fragility of vaccine production system. Science 2004;306:385.
64. Framework of Government preparedness plan for influenza pandemic. Hong Kong Centre for Health Protection website: www.chp.gov.hk/files/pdf/ flu_plan_framework_en_20050222. pdf. Accessed 26 Apr 2005.